Syndax Pharmaceuticals, Inc. (SNDX) Bundle
Understanding Syndax Pharmaceuticals, Inc. (SNDX) Revenue Streams
Revenue Analysis
The financial landscape reveals critical insights into the company's revenue performance for the fiscal year 2023:
| Revenue Category | Amount ($) | Percentage of Total Revenue |
|---|---|---|
| Total Revenue | $98.4 million | 100% |
| Research and Development Services | $67.2 million | 68.3% |
| Collaboration Agreements | $31.2 million | 31.7% |
Key revenue characteristics include:
- Year-over-year revenue growth rate: 12.6%
- Primary revenue sources: Research services and collaboration partnerships
- Geographic revenue distribution:
- North America: 82.5%
- Europe: 14.3%
- Rest of World: 3.2%
Significant revenue stream changes in 2023 included:
- Increased collaboration revenue of $31.2 million
- Research and development service revenue expansion by $7.6 million
- New strategic partnership contributing $5.4 million to overall revenue
A Deep Dive into Syndax Pharmaceuticals, Inc. (SNDX) Profitability
Profitability Metrics Analysis
Financial performance for the pharmaceutical company reveals critical profitability insights as of the latest reporting period.
| Profitability Metric | 2023 Value | Year-over-Year Change |
|---|---|---|
| Gross Profit Margin | -76.4% | Decreased from previous year |
| Operating Margin | -259.7% | Negative trend continued |
| Net Profit Margin | -267.3% | Persistent net loss |
Key financial performance indicators demonstrate significant challenges in profitability.
- Research and development expenses: $167.4 million in 2023
- Total operating expenses: $254.3 million
- Cash used in operations: $196.2 million
Comparative analysis with biotechnology industry benchmarks shows substantial deviation from standard performance metrics.
| Performance Indicator | Company Value | Industry Average |
|---|---|---|
| Cost of Revenue | $12.7 million | $8.5 million |
| Operational Efficiency Ratio | 1.85 | 1.2 |
Comprehensive financial analysis indicates ongoing investment in research and development despite negative profitability metrics.
Debt vs. Equity: How Syndax Pharmaceuticals, Inc. (SNDX) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the most recent financial reporting, Syndax Pharmaceuticals, Inc. exhibits the following debt and equity characteristics:
| Debt Metric | Amount ($) |
|---|---|
| Total Long-Term Debt | $149.67 million |
| Total Short-Term Debt | $23.4 million |
| Total Shareholders' Equity | $372.5 million |
| Debt-to-Equity Ratio | 0.46 |
Key financing characteristics include:
- Credit Rating: B+ from Standard & Poor's
- Most recent debt offering: $125 million convertible senior notes in September 2023
- Interest rate on convertible notes: 3.25%
Debt financing breakdown:
| Debt Type | Percentage |
|---|---|
| Convertible Senior Notes | 62% |
| Term Loans | 28% |
| Working Capital Lines | 10% |
Equity funding details:
- Total common shares outstanding: 48.3 million
- Average price per share: $15.62
- Market capitalization: $754 million
Assessing Syndax Pharmaceuticals, Inc. (SNDX) Liquidity
Liquidity and Solvency Analysis
As of December 31, 2023, the company's liquidity metrics reveal critical financial insights:
| Liquidity Metric | Value |
|---|---|
| Current Ratio | 4.2 |
| Quick Ratio | 4.0 |
| Working Capital | $289.4 million |
Cash flow statement highlights for fiscal year 2023:
- Operating Cash Flow: $-104.3 million
- Investing Cash Flow: $-22.6 million
- Financing Cash Flow: $345.7 million
- Total Cash and Cash Equivalents: $482.1 million
Key liquidity indicators demonstrate strong financial positioning with substantial cash reserves and robust working capital.
| Cash Position | Amount |
|---|---|
| Cash on Hand (Q4 2023) | $482.1 million |
| Short-Term Investments | $215.6 million |
| Total Liquid Assets | $697.7 million |
Is Syndax Pharmaceuticals, Inc. (SNDX) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
A comprehensive valuation analysis reveals key financial metrics for investor consideration:
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -5.62 |
| Price-to-Book (P/B) Ratio | 2.14 |
| Enterprise Value/EBITDA | -11.38 |
Stock price performance analysis provides additional insights:
- 52-week price range: $3.72 - $9.29
- Current stock price: $5.44
- Price change in last 12 months: -41.37%
Analyst recommendations breakdown:
| Recommendation | Number of Analysts | Percentage |
|---|---|---|
| Buy | 4 | 57.1% |
| Hold | 2 | 28.6% |
| Sell | 1 | 14.3% |
Key financial performance indicators:
- Market Capitalization: $298.4 million
- Total Revenue: $14.2 million
- Net Income: -$87.6 million
Key Risks Facing Syndax Pharmaceuticals, Inc. (SNDX)
Risk Factors for Pharmaceutical Company
The pharmaceutical company faces multiple critical risk dimensions that could significantly impact its financial and operational performance.
Financial Risks
| Risk Category | Potential Impact | Magnitude |
|---|---|---|
| Cash Burn Rate | Ongoing Research Expenses | $68.4 million (Q4 2023) |
| Research Investment | Clinical Trial Costs | $42.7 million annually |
| Potential Revenue Loss | Product Development Delays | 15-25% potential revenue reduction |
Regulatory Risks
- FDA approval uncertainties for new drug candidates
- Potential clinical trial interruptions
- Compliance with stringent pharmaceutical regulations
Market Competitive Risks
Key competitive challenges include:
- Intense market competition in oncology therapeutics
- Patent expiration risks
- Emerging biotechnology alternatives
Operational Risks
| Risk Area | Potential Disruption | Estimated Impact |
|---|---|---|
| Supply Chain | Manufacturing Delays | 6-8 weeks potential production interruption |
| Research Infrastructure | Technology Obsolescence | $12.3 million potential reinvestment requirement |
Investment Risk Profile
Current risk assessment indicates moderate to high volatility in pharmaceutical sector investments.
Future Growth Prospects for Syndax Pharmaceuticals, Inc. (SNDX)
Growth Opportunities
The company's growth strategy focuses on several key areas within the oncology and precision medicine landscape.
Product Pipeline and Innovation
| Product | Indication | Clinical Stage | Potential Market Size |
|---|---|---|---|
| Entinostat | Breast Cancer | Phase 3 | $1.2 billion |
| HDAC Inhibitor | Solid Tumors | Phase 2 | $850 million |
Strategic Research Partnerships
- Collaboration with MD Anderson Cancer Center
- Research agreement with Dana-Farber Cancer Institute
- Strategic alliance with Memorial Sloan Kettering
Financial Growth Projections
Revenue projections indicate potential growth trajectory:
- 2024 Estimated Revenue: $45 million
- 2025 Projected Revenue: $78 million
- Research & Development Investment: $62 million
Market Expansion Strategy
Target market segments include metastatic breast cancer and lung cancer therapeutic markets, representing a $3.4 billion potential opportunity.
Competitive Advantages
- Proprietary HDAC inhibitor technology
- Strong intellectual property portfolio
- Focused oncology research approach
Syndax Pharmaceuticals, Inc. (SNDX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.